Drug-eluting stents: The panacea for restenosis?

Singapore Medical Journal

Volumn 45, Issue 7, 2004, Pages 300-302

  Lim, Michael Chun Leng ^a  

^a MOUNT ELIZABETH MEDICAL CENTRE   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; IMMUNOSUPPRESSIVE AGENT; PACLITAXEL; POLYMER; RAPAMYCIN; TARGET OF RAPAMYCIN KINASE;

ARTERY INTIMA PROLIFERATION; ATHERECTOMY; BARE METAL STENT; BRACHYTHERAPY; CLINICAL TRIAL; CORONARY ARTERY DISEASE; CORONARY ARTERY OBSTRUCTION; CORONARY STENT; COST; DRUG ELUTING STENT; EDITORIAL; HUMAN; ISCHEMIC HEART DISEASE; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; RESTENOSIS;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANTI-BACTERIAL AGENTS; ANTINEOPLASTIC AGENTS; COATED MATERIALS, BIOCOMPATIBLE; CORONARY ARTERIOSCLEROSIS; CORONARY RESTENOSIS; COST-BENEFIT ANALYSIS; DRUG DELIVERY SYSTEMS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; PACLITAXEL; POLYMERS; RANDOMIZED CONTROLLED TRIALS; SIROLIMUS; STAINLESS STEEL; STENTS;

EID: 3142624498     PISSN: 00375675     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Editorial

References (23)

1. Serruys PW, de Jaegere P, Kiemeneij F, Macaya C, Rutsch W, Heyndrickx G, et al. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. N Engl J Med 1994; 331:489-95.
2. Fischman DL, Leon MB, Baim DS, Schatz RA, Savage MP, Penn I, et al. A randomized comparison of coronary stent placement and balloon angioplasty in the treatment of coronary artery disease. N Engl J Med 1994; 331:496-501.
3. Macaya C, Serruys PW, Ruygrok P, Suryapranata H, Mast G, Klugmann S, et al. Continued benefit of coronary stenting versus balloon angioplasty: one-year clinical follow-up of Benestent trial. J Am Coll Cardiol 1996; 27:255-61.
4. Morice MC, Serruys PW, Sousa JE, Fajadet J, Ban Hayashi E, Perin M, et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 2002; 346:1773-80.
5. Grube E, Silbar SM, Hauptmann KE, Mueller R, Buellesfeld L, Gerckens U, et al. TAXUS: 6- and 12-month results from a randomized, doubled-blind trial on a slow-release paclitaxel-eluting stent for de novo coronary lesions. Circulation 2003; 107:38-42.
6. Marx SO, Marks AR. Bench to bedside: the development of rapamycin and its application to stent restenosis. Circulation 2001; 104:852-5.
7. Moses JW, Leon MB, Pompa JJ, Fitzgerald PJ, Holmes DR, O'Shaughnessy C, et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 2003; 349:1315-24.
8. Ellis S, Stone GW, Pompa JJ, et al. The TAXUS IV study: final angiographic results (abstract). Circulation 2003; 108 (Suppl IV):IV-532.
9. Lemos PA, Serruys PW, Sousa JE. Drug-eluting stents: cost versus clinical benefit. Circulation 2003; 107:3003-7.
10. O'Neil WW, Leon MB. Drug-eluting stents: cost versus clinical benefit. Circulation 2003; 107:3008-11.
11. Schofer J, Schluter M, Gershlick AH, Wijns W, Garcia E, Schampaert E, et al, for the E-SIRIUS. Sirolimus-eluting stents for treatment of patients with long atherosclerotic lesions in small coronary arteries: double-blind, randomized controlled trial (E-SIRIUS). Lancet 2003; 362:1093-9.
12. Schampaert E. The Canadian multicenter, randomized, double-blinded trial of sirolimus-eluting stent in the treatment of patients with denovo coronary artery lesions (C-SIRIUS): 365-day complete follow-up (abstract). Circulation 2003; 108 (Suppl IV):IV-703.
13. Lemos P, Serruys PW, van Domburg RT, Saia F, Arampatzis CA, Hoye A, et al. Unrestricted utilization of sirolimus-eluting stents compared with conventional bare stent implantation in the "real world": the Rampamycin-eluting stent evaluated at Rotterdam Cardiology Hospital (Research) registry. Circulation 2004; 109:190-5.
14. Abizaid A, Chan C, Kaul U, et at. "Real world" evaluation of slow-release, polymer-based, paclitaxel-eluting TAXUS stents in native coronary arteries: the WISDOM international registry (abstract). Circulation 2003; 108 (Suppl IV):IV-534.
15. Guagliumi G, Sousa E, Urban P, et al. Sirolimus-eluting stent in routine clinical practice: a 6-minth follow up report from the international e-CYPHER registry (abstract). Circulation 2003; 108 (Suppl IV):IV-534.
16. Arampatzis CA, Lemos PA, Tanabe K, Hoye A, Degertekin M, Saia F, et al. Effectiveness of sirolimus-eluting stent for treatment of left main coronary artery disease. Am J Cardiol 2003; 92:327-9.
17. Colombo A, Stankovic G, Orlic D, Corvaja N, Liistro F, Airoldi F, et al. Modified T-stenting technique with crushing for bifurcation lesions: immediate results and 30-day outcome. Catheter Cardiovasc lnterv 2003; 60:145-51.
18. Nakamura S, Muthusamy TS, Bae J-H, et al. Impact of sirolimus-eluting stents on the outcome of patients with chronic total occlusions: multicenter registry in Asia (abstract). Circulation 2003; 108 (Suppl IV):IV-409.
19. Saia F, Lemos PA, Lee CH, Arampatzis CA, Hoye A, Degertekin M, et al. Sirolimus-eluting stent implantation in ST-elevation acute myocardial infarction: a clinical angiographic study. Circulation 2003; 108:1927-9.
20. Degertekin M, Saia F, Lemos PA, Arampatzis CA, Serruys PW. Sirolimus-eluting stents for the treatment of in-stent restenosis. Minerva Cardioangiol 2003; 51:475-84.
21. Sousa JE, Serruys PW, Costa MA. New frontiers in cardiology drug eluting stents: part I. Circulation 2003; 107:2274-9.
22. Sousa JE, Serruys PW, Costa MA. New frontiers in cardiology drug eluting stents: part II. Circulation 2003; 107:2383-9.
23. Lau KW, Johan A, Sigwart U, Hung JS. A stent is not just a stent: stent construction and design do matter in its clinical performance. Singapore Med J 2004; 45:305-12.